Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
IO-108(一种抗LILRB2抗体)治疗晚期实体瘤患者的I期剂量递增研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-010006
Taylor, Matthew H; Naing, Aung; Powderly, John; Woodard, Paul; Chung, Luke; Lin, Wen Hong; Tian, Hongyu; Siemers, Nathan; Xiang, Hong; Deng, Rong; Hong, Kyu; Valencia, Donna; Huang, Tao; Zhu, Ying; Liao, X Charlene; Schebye, Xiao Min; Patel, Manish R